Nonetheless, these pre-clinical investigations have shown that MARCKS can serve as a druggable target in MM, although further validation in other hematological malignancies will add value to the clinical application of several such MARCKS-targeting inhibitors as potential therapeutic agents in blood cancers. The gene discussed is MARCKS; the disease is hematopoietic and lymphoid system neoplasm.